Results 81 to 90 of about 30,618 (276)

Pharmacogenetics and personalized medicine

Saúde & Tecnologia, 2016
Pharmacogenetics aims to identify genetic differences between individuals that may influence the response to drug therapy, improving their effectiveness and safety. Associated with the pharmacogenetics emerges ‘personalized medicine’.
Miguel Brito
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine

Background/Objectives: The clinical implementation of pharmacogenetics (PGx) remains limited, even for well-established drug–gene interactions. In addition to insufficient infrastructure and PGx education among healthcare professionals, there is ...
María Teresa Nieto-Sánchez, Alicia Torres-García, Emilio Fernández-Varón, Isabel Blancas, Rocío Morón, Xando Díaz-Villamarín, José Cabeza-Barrera, María Martínez-Pérez   +7 more
core   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park, Yitian Zhou, Volker M. Lauschke   +2 more
wiley   +1 more source

A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation

Nature Communications
Inflammatory bowel disease (IBD) arises from genetic-environmental interactions. Adenosine deaminases acting on RNA 1 (ADAR), an RNA-editing enzyme converting adenosine (A) to inosine (I), is essential for tissue homeostasis.
Pengfei Xu, Yue Xi, Jong-Won Kim, Min Zhang, Chen Gao, Yue Wang, Meishu Xu, Xingchen Wang, Songrong Ren, Da Yang, Qingde Wang, Wen Xie   +11 more
doaj   +1 more source

Pharmacogenetics and forensic toxicology

, 2010
Large inter-individual variability in drug response and toxicity, as well as in drug concentrations after application of the same dosage, can be of genetic, physiological, pathophysiological, or environmental origin.
Musshoff, Frank, Madea, Burkhard, Burkhard Madea, Frank Musshoff, Ulrike M. Stamer, Stamer, Ulrike M   +5 more
core   +1 more source

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

Clinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A. Bousman, Evangelia Eirini Tsermpini, Michelle Whirl‐Carrillo, Amy J. Turner, Volker M. Lauschke, Mohamed Nagy, Erin C. Boone, Teri E. Klein, Pablo Zubiaur, Andrea Gaedigk   +13 more
wiley   +1 more source

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

Clinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples, Shayna R. Killam, Karen E. Brown, Rachel Dalton, Elizabeth Sather, Qiang Chen, Joshua Loveland, Corbin Schwanke, Abdallah F. Elias, Kristin L. Bigos, Erica L. Woodahl   +10 more
wiley   +1 more source

Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists

, 2015
Taku Obara,1–3 Shinya Abe,4 Michihiro Satoh,1 Sergio Ramón Gutiérrez Ubeda,5 Shoko Yoshimachi,4 Teruaki Goto4 1Department of Pharmacy, Tohoku University Hospital, Sendai, 2Division of Molecular Epidemiology, Environment and Genome ...
Obara T, Abe S, Yoshimachi S, Gutiérrez Ubeda SR, Satoh M, Goto T   +5 more
core